Highlights d Astrocytes regulate synapse maturation by controlling AMPA receptor subtype d Astrocyte-secreted Chrdl1 increases synaptic levels of GluA2 AMPA receptors d Chrdl1 KO mice have immature synapses d Chrdl1 KO mice show enhanced plasticity in vivo, which is maintained into adulthood
Correspondence nallen@salk.edu In Brief Blanco-Suarez et al. identify that synapse maturation is not intrinsic to neurons but is regulated by neighboring astrocytes. They demonstrate that astrocytesecreted Chrdl1 increases GluA2 AMPA receptor levels at synapses, inducing synapse maturation and inhibiting plasticity.
INTRODUCTION
An important step in the development of the CNS is the maturation and stabilization of appropriate synaptic connections between neurons, ensuring that correct pathways remain functional throughout life. A major component of excitatory glutamatergic synapse maturation is a switch in the subtype of AMPA glutamate receptor (AMPAR) present at excitatory synapses from calcium-permeable to GluA2-containing calcium-impermeable channels (Brill and Huguenard, 2008; Kumar et al., 2002) . This switch in AMPARs contributes to synapse maturation and stabilization by decreasing the entry of calcium into the postsynaptic cell, limiting plasticity mechanisms that require signaling through calcium-dependent pathways (Henley and Wilkinson, 2016; Jia et al., 1996; Traynelis et al., 2010) . The molecular mechanisms that underlie this switch in AMPARs in the context of development remain unknown.
AMPA glutamate receptors (AMPARs) conduct fast synaptic signals at excitatory glutamatergic synapses (Traynelis et al., 2010) . There are 4 AMPAR subunits (GluA1-4), which assemble into tetramers (Traynelis et al., 2010) . AMPAR composition determines synaptic properties (e.g., the duration of the synaptic response and whether calcium permeates the channel). During cortical development, the switch from calcium-permeable to GluA2-containing calcium-impermeable AMPARs occurs at specific times in each cortical layer, occurring first in layer 4 neurons at postnatal day 7 (P7) to P8, then in layer 2/3 neurons at P12-P14, and finally in layer 5 neurons at P15-P16 (Brill and Huguenard, 2008; Kumar et al., 2002) . Conflicting results exist about whether neuronal activity is required to promote the subunit switch of AMPARs, with some studies showing it is necessary and others that the switch occurs independently of activity (Liu and Cull-Candy, 2000; Zhu et al., 2000) . Whether this switch is intrinsic to neurons or regulated by other cells is not known.
Astrocytes are the main class of glial cells in the CNS (Khakh and Sofroniew, 2015) . During development, astrocytes secrete multiple signals that induce formation or elimination of synapses and regulate synaptic strength (Clarke and Barres, 2013) . We previously showed that astrocyte-secreted glypicans 4 and 6 (Gpc4 and Gpc6) specifically recruit GluA1 calcium-permeable AMPARs to synapses, promoting the formation of immature synapses . However, Gpc4 and Gpc6 have no effect on GluA2 clustering . Based on this, we hypothesize that astrocytes can regulate the subunit composition of AMPARs at synapses by releasing distinct signals, with Gpc4 and Gpc6 inducing nascent immature GluA1-containing synapses and a second factor promoting synapse maturation by increasing synaptic levels of calcium-impermeable GluA2containing AMPARs. In the present study, we identify chordin-like 1 (Chrdl1) as the astrocyte-secreted factor responsible for increasing synaptic GluA2 AMPARs. Chrdl1 has been classified as a member of the chordin family of secreted bone morphogenetic protein (BMP) antagonists due to sequence homology (Nakayama et al., 2001; Sakuta et al., 2001) . Chrdl1 has three cysteine-rich (CR) repeats, which are homologous to von Willebrand factor C (vWFC) domains. Chrdl1 can bind multiple BMP ligands, with no detectable binding to other members of the transforming growth factor b (TGF-b) superfamily, including activin and TGF-b (Nakayama et al., 2001) . BMP signaling has been shown to promote synaptogenesis at the Drosophila neuromuscular junction (Ball et al., 2015; Berke et al., 2013; Fuentes-Medel et al., 2012) and in vertebrates (Shen et al., 2004; Xiao et al., 2013) . Alternatively, Chrdl1 may act in a BMP-independent manner by interacting with additional ligands via its vWFC domains. There is precedent for this from other astrocyte-secreted synaptogenic factors. For example, Gpc4 was identified as a molecule that binds and sequesters growth factors in the extracellular space via its glycosaminoglycan side chains (Hagihara et al., 2000) , analogous to Chrdl1 binding and sequestering BMPs. However, we identified that the mechanism Gpc4 uses to recruit GluA1 AMPARs to synapses is independent of this function and instead is via Gpc4 signaling through a presynaptic receptor (Farhy-Tselnicker et al., 2017) .
Here, we performed a biochemical screen and identified Chrdl1 as the astrocyte-secreted protein necessary and sufficient to regulate GluA2 synaptic levels and synapse maturation. We find that in vivo expression of Chrdl1 in astrocytes has both temporal and regional heterogeneity, peaking in the cortex at the time of synapse maturation. We demonstrate that Chrdl1 knockout (KO) mice show enhanced remodeling in response to altered sensory input, showing that Chrdl1 is repressing plasticity in vivo. These findings identify an important role for non-neuronal cells in the sculpting of neural circuits and have implications for understanding synapse maturation during development and the regulation of synaptic plasticity in the adult.
RESULTS
Astrocytes Secrete a Factor that Is Sufficient to Increase GluA2 AMPARs at Synapses To directly identify the astrocyte-secreted factor that is sufficient to increase synaptic GluA2 AMPARs, we carried out a screen using cultured retinal ganglion cell (RGC) neurons isolated from the rat retina Ullian et al., 2001) . RGCs cultured in the absence of other cell types form few synapses and show little synaptic activity. Adding astrocytes or factors secreted by astrocytes (astrocyte conditioned media [ACM]) for 6 days greatly increases RGC synapse number, synaptic activity, and surface AMPARs, making this a robust system to identify astrocytesecreted proteins that regulate synapses Ullian et al., 2001) . To assay surface levels of GluA2 AMPARs on RGC dendrites, we used a live immunostaining assay on nonpermeabilized cells, with an antibody specific to the N-terminal region of GluA2. We found that RGCs grown in the presence of astrocytes or ACM for 6 days have a significant $2-fold increase in surface clusters of GluA2 AMPARs ( Figures 1A and 1B ; astrocyte, 2.37-fold ± 0.53-fold; ACM, 1.91-fold ± 0.30-fold compared to alone), demonstrating that astrocytes secrete a factor that is sufficient to increase levels of GluA2 AMPARs at synapses.
Biochemical Screen to Identify the Astrocyte-Secreted GluA2 Clustering Factor
To determine which factor being secreted by astrocytes is sufficient to increase surface GluA2 clusters on RGC neurons, we fractionated factors present in ACM based on charge using an anion exchange chromatography column. Column fractions were assayed for the ability to increase surface GluA2 on RGC dendrites, and this identified the unbound fraction from an anion exchange column as sufficient (Figures 1C and 1D; astrocyte, bound, unbound, -fold compared to alone). We used mass spectrometry analysis to identify the proteins present in the anion exchange column unbound fraction, generating a list of 50 candidates (Table S1 ). To narrow down proteins for testing, we compared the most abundant extracellular proteins detected in the positive fraction with published mRNA expression data from purified brain cells (Cahoy et al., 2008) . We focused on proteins that (1) are enriched in astrocytes and absent from neurons, as we hypothesized that this will be a factor specifically made by astrocytes in vivo; and (2) peak in expression in astrocytes at P14, the time when GluA2 is being recruited to synapses (Brill and Huguenard, 2008) . This narrowed down the list to three candidates: chitinase 3-like 1 (Chi3l1), Chrdl1, and thrombospondin 4 (Thbs4). To determine if any of these proteins is sufficient by itself to increase surface clustering of GluA2, we treated RGCs with purified protein for each candidate at multiple doses (4 ng to 1 mg/mL) for 6 days. Chi3l1 and Thbs4 did not cause a significant increase in surface clustering of GluA2 at any dose tested (Figures 1E and 1F) . Chrdl1 was sufficient to significantly increase surface clusters of GluA2 by $2-fold at multiple doses (0.1-1 mg/mL; Figure 1G ), identifying Chrdl1 as a factor secreted by astrocytes that regulates surface clustering of GluA2 AMPARs.
Chrdl1 Is Secreted by Astrocytes and Is Necessary and Sufficient to Increase GluA2 Clustering and Formation of Active Synapses
Having identified Chrdl1 via mass spectrometry analysis, we next validated that astrocytes in vitro are secreting Chrdl1 protein. Western blotting of ACM detected Chrdl1 protein, whereas RGC conditioned media did not contain Chrdl1, showing astrocytes and not neurons are secreting Chrdl1 protein in vitro (Figures S1A and S1B). We then determined the extent of Chrdl1 effects on multiple aspects of synapse formation and function in vitro by treating RGC neurons with purified Chrdl1 protein at 1 mg/mL for 6 days (a level of protein similar to that being secreted by astrocytes into ACM in vitro; Figure S1C ), the treatment used in all subsequent experiments unless noted. Chrdl1 increased surface clustering of GluA2 to the same level as astrocytes, suggesting that Chrdl1 is a major contributor to this astrocyte function (Figures 2A and 2B; astrocyte, 2. 15-fold ± 0.24-fold; Chrdl1, 1.99-fold ± 0.24-fold compared to alone). To address this directly, we used immunodepletion to remove Chrdl1 from ACM and compared the ability of Chrdl1-depleted ACM to mock-depleted ACM to increase surface GluA2 (Figure S1D) . This demonstrated that Chrdl1-depleted ACM no longer increased surface GluA2 compared to the untreated condition, whereas mock-depleted ACM induced a significant $2-fold increase in surface GluA2 (Figures 2C and 2D; Chrdl1, 2. 63-fold ± 0.42-fold; ACM, 2.51-fold ± 0.36-fold; Chrdl1depleted ACM, 1.27-fold ± 0.22-fold; mock-depleted ACM, 2.29-fold ± 0.47-fold compared to alone).
To determine if Chrdl1 is sufficient to increase synapse formation, we used immunocytochemistry to label pre-and postsynaptic markers (with Bassoon and PSD95, respectively), scoring colocalization of synaptic markers as a synapse (Ippolito and Eroglu, 2010) . Chrdl1 was sufficient to increase synapse number by $3-fold, an effect similar to that induced by astrocytes (Figures 2E and 2F; astrocyte, Chrdl1, 3. 15-fold ± 0.30-fold compared to alone).
Given an increase in synapses containing GluA2 AMPARs, we next asked if these synapses are functionally active. We used whole-cell patch clamping to record individual miniature excit-atory postsynaptic currents (mEPSCs) from RGCs in the presence of tetrodotoxin to block action potentials ( Figures 2G-2I ). Chrdl1 induced a significant increase in the frequency of mEPSCs detected, to the same level as astrocytes (Figures 2J and S1E; alone, 0.55 ± 0.12 Hz; astrocyte, 1.58 ± 0.21 Hz; Chrdl1, 2.84 ± 1.17 Hz). Chrdl1 did not induce a significant change in mEPSC amplitude compared to RGCs alone (Figures 2K and S1F; alone, 11.03 ± 0.93 pA; astrocyte, 19.25 ± 1.16 pA; Chrdl1, 12.28 ± 0.61 pA) , whereas mEPSC decay time was significantly decreased by Chrdl1 treatment ( Figure 2L ; alone, 1.58 ± 0.12 ms; astrocyte, 1.88 ± 0.13 ms; Chrdl1, 1.19 ± 0.13 ms). Taken together, these (A) Example images of RGC neurons cultured alone, with an astrocyte feeder layer, or astrocyte conditioned media (ACM) for 6 days. Top: red labels whole neurons, and green labels surface GluA2. Bottom: zoom-in view of a dendrite (GluA2, white). Arrowheads mark example GluA2 clusters. (B) Quantification of (A), where surface GluA2 is normalized to RGCs alone. An example experiment (n = 29-30 cells per condition), repeated >3 times with the same result, is shown. (C and D) Column fractionation of ACM identified the GluA2 clustering activity in the unbound fraction from an anion column. (C) Example images, as in (A). (D) Quantification of (C); an example experiment (n = 30 cells per condition), repeated >3 times with same result, is shown. (E-G) Testing candidate proteins for GluA2 clustering activity. RGCs were treated with multiple doses of purified recombinant proteins for 6 days and assayed for surface clustering of GluA2. Chitinase 3-like 1 (Chi3l1) (E) and thrombospondin 4 (Thbs4) (F) had no effect; chordin-like 1 (Chrdl1) (G) significantly increased surface clustering of GluA2 at multiple doses. Example experiments are shown (n = 29-30 cells per condition); Chi3l1 and Thbs4 experiments were repeated twice and Chrdl1 experiments were repeated 3 times, with the same result. Scale bars, 10 mm. Bar graphs represent mean ± SEM. Statistics by one-way ANOVA; significance as stated on the graph compared to alone. See also Table S1. (legend continued on next page) data demonstrate that astrocyte-secreted Chrdl1 is necessary and sufficient to induce the formation of mature functional excitatory synapses containing GluA2 AMPARs, differentiating it from astrocyte-secreted Gpc4, which induces formation of immature nascent synapses containing GluA1 Farhy-Tselnicker et al., 2017) .
Chrdl1
Regulates GluA2 AMPARs in Neurons in a BMP-Independent Manner Chrdl1 was identified and classified as a member of the chordin family of secreted BMP antagonists due to sequence homology (Coffinier et al., 2001; Nakayama et al., 2001; Sakuta et al., 2001; Ueki et al., 2003) . BMP signaling is involved in synaptogenesis (Ball et al., 2015; Berke et al., 2013; Fuentes-Medel et al., 2012; Kalinovsky et al., 2011; Xiao et al., 2013) and dendritic outgrowth (Beck et al., 2001; Esquenazi et al., 2002; Withers et al., 2000) through both SMAD-dependent (transcriptional activation of target genes) and SMAD-independent mechanisms (Lee-Hoeflich et al., 2004; Liu and Niswander, 2005) . Therefore, a possible mechanism for how astrocyte-secreted Chrdl1 regulates GluA2 AMPARs is by antagonizing ongoing BMP signaling in neurons.
We first asked if there is any evidence of Chrdl1 regulating canonical BMP signaling in neurons by controlling the recruitment of phospho-SMAD (pSMAD) to the nucleus, a necessary step for pSMAD to regulate transcription of BMP target genes (Liu and Niswander, 2005) . We found no difference in the level of nuclear pSMAD in RGCs grown alone or treated with Chrdl1 for 1 or 6 days, whereas treatment with BMP4 as a positive control caused a robust nuclear recruitment of pSMAD (Figures 3A and 3B; 1-day treatment: BMP4, 1.94-fold ± 0.11-fold; Chrdl1, 1.08-fold ± 0.05-fold compared to alone; 6 day treatment: BMP4, 2.05-fold ± 0.09-fold; Chrdl1, 1.09-fold ± 0.10-fold compared to alone). We then used an unbiased approach to ask if Chrdl1 regulates expression of BMP target genes, by performing RNA sequencing of RGCs treated with Chrdl1 compared to untreated neurons. We found that Chrdl1 treatment of RGCs did not alter the expression of genes related to BMP signaling (Table S2 ) or genes involved in excitatory synaptogenesis and AMPAR trafficking (Table S3 ). The inability of Chrdl1 to alter the translocation of pSMAD to the nucleus or regulate expression of BMP target genes indicates Chrdl1 is likely acting independently of the canonical BMP signaling cascade.
The RNA-sequencing analysis showed that RGCs express mRNA for multiple BMP family members, including BMP2, BMP4, BMP6, and BMP7, making inhibition of their action through a non-canonical BMP pathway a possible mechanism (Table S2 ). If Chrdl1 is regulating non-canonical BMP signaling in RGC neurons, then we predict that other secreted antagonists of BMP signaling should have the same effect as Chrdl1 in regulating GluA2 AMPARs by preventing BMP-receptor interaction. We tested two secreted BMP antagonists that bind the same BMPs as Chrdl1: chordin (binds BMP2, BMP4, and BMP7) and noggin (binds BMP2, BMP4, BMP5, BMP6, and BMP7) (Bragdon et al., 2011) . We first validated that the BMP antagonists were functional by demonstrating they were sufficient to decrease nuclear recruitment of pSMAD in response to BMP4 in HEK cells (Figures S1G and S1H). Treating RGC neurons for 6 days with either chordin or noggin did not cause an increase in surface GluA2 clusters on RGC dendrites compared to untreated RGCs, whereas Chrdl1 applied in the same experiment did (Figures 3C and 3D; Chrdl1 1 mg/mL, 1.75-fold ± 0.25-fold; Chrdl1 2.5 mg/mL, 1.66-fold ± 0.29-fold; chordin 2.5 mg/mL, 0.91-fold ± 0.11-fold; noggin 2.5 mg/mL, 0.96-fold ± 0.07-fold compared to alone). The inability of chordin or noggin to phenocopy the effect of Chrdl1 indicates BMP signaling is not involved in Chrdl1-mediated GluA2 recruitment.
We finally asked if adding excess BMP ligand to saturate the CR repeats (BMP-binding sites) on Chrdl1 would inhibit the ability of Chrdl1 to increase surface levels of GluA2. Chrdl1 shows a high affinity for BMP4 and a lower affinity for BMP7 (Nakayama et al., 2001) . High levels of BMP4 (250 ng/mL) blocked the ability of Chrdl1 to increase surface clustering of GluA2, and BMP7 partially blocked the effect, showing that the CR repeats (BMPbinding sites) are necessary for Chrdl1 to increase surface GluA2 ( Figures 3E and 3F ; Chrdl1, 2.01-fold ± 0.16-fold; Chrdl1+BMP4, 0.81-fold ± 0.03-fold; Chrdl1+BMP7, 1.26fold ± 0.02-fold compared to alone). Additionally, if ongoing BMP signaling were regulating surface GluA2 in RGC neurons, then we predict that treatment with BMPs themselves would decrease surface levels of GluA2. However, treatment with either BMP4 or BMP7 in the absence of Chrdl1 did not significantly alter surface levels of GluA2 on RGCs compared to the untreated condition ( Figures 3E and 3F ; BMP4, 0.86-fold ± 0.03-fold; BMP7, 0.88-fold ± 0.09-fold compared to alone), showing that BMPs are not regulating synaptic levels of GluA2 AMPARs in RGCs. Taken together, these results strongly suggest that the mechanism Chrdl1 uses to increase GluA2 AMPARs at synapses is independent of BMP signaling and is instead through a novel pathway regulated by the CR repeats in Chrdl1. (A) Example images of RGCs treated with 1 mg/mL Chrdl1 or 250 ng/mL BMP4 for 1 day and immunostained for pSMAD (red) and DAPI to mark the nucleus (blue). BMP4 is a positive control condition and is sufficient to increase nuclear pSMAD. (B) Quantification of (A), with the nuclear pSMAD level normalized to alone. n = 3 experiments, each with 30 cells per condition (both 1-day and 6-day treatment). (C and D) Other secreted BMP antagonists do not increase surface clustering of GluA2 in RGCs. (C) Example images of RGC neurons treated with Chrdl1, chordin, or noggin for 6 days, with concentration as marked. Top: red labels neurons, and green labels surface GluA2. Bottom: zoom-in view of a dendrite (GluA2, white). Arrowheads mark example GluA2 clusters. (D) Quantification of (C), with surface GluA2 compared to RGC neurons alone (untreated). n = 3 experiments, each with 30 cells per condition.
(legend continued on next page)
Chrdl1 Is Enriched in Astrocytes In Vivo and Shows Heterogeneous Spatiotemporal Expression
Having demonstrated Chrdl1 is an astrocyte-secreted factor that regulates synaptic GluA2 AMPARs and synapse maturation in vitro, we next examined the role of Chrdl1 in the developing brain. We analyzed the regional and temporal expression of Chrdl1 mRNA using in situ hybridization in brain sections from mice at multiple ages: P7 (initiation of synaptogenesis), P12 (initiation of synapse maturation), P30 (stable synapses), and P120 (adult). Expression of Chrdl1 was detected at all ages and showed a heterogeneous pattern, being restricted to the cortex, striatum, and cerebellum (of note, cerebellar Chrdl1 expression is in Purkinje neurons, not astrocytes) (Figures 4A, S2A-S2C, and S4C). Interestingly, even within the cortex, Chrdl1 expression is heterogeneous, being enriched in upper cortical layers compared to deep layers (Figures 4A and S2A-S2C).
To determine if astrocytes are the major source of Chrdl1 in the cortex in vivo, we used fluorescent in situ hybridization (FISH) to detect Chrdl1 mRNA, along with an astrocyte marker (Aldh1l1 or GLAST) and a neuronal marker (Tubb3). Strong overlap between Chrdl1 and the astrocyte marker (Aldh1l1 or GLAST) was detected at all ages in the upper layers of the visual cortex, with minimal overlap between Chrdl1 and Tubb3 (Figures 4B and S3A-S3C). At P12, 82% of the Chrdl1 mRNA overlaps with Aldh1l1 mRNA, showing in vivo Chrdl1 mRNA is enriched in astrocytes ( Figure 4C ; Chrdl1 overlap with Aldh1l1 [81.6% ± 1.6%], Tubb3 [13.5% ± 0.2%], other [4.9% ± 1.5%]). Further evidence for astrocyte-enriched expression of Chrdl1 comes from published RNA-sequencing data, which shows that Chrdl1 is enriched in astrocytes compared to other cell types in the developing cortex ( Figure S4D ) (Zhang et al., 2014) . To determine if the level of Chrdl1 varies across development, we used qRT-PCR to quantify Chrdl1 mRNA level in the whole visual cortex (P7, P12, P21, P30, and P120), and specifically in astrocytes in the visual cortex (P7 and P14), at multiple postnatal time points. We found that Chrdl1 is expressed at every time point examined ( Figure 4D ) and peaks in expression at P12-P14, with astrocytespecific expression of Chrdl1 increasing by 2.57-fold ± 0.50-fold between P7 and P14 ( Figure 4E ). This matches the time when the switch to GluA2 AMPARs and synapse maturation is occurring in the upper cortical layers, where Chrdl1 expression is highest (Brill and Huguenard, 2008) . Therefore, Chrdl1 is expressed by astrocytes in the cortex and peaks at the right time to be regulating the AMPAR switch and synapse maturation in vivo.
Chrdl1 Absence Does Not Disrupt Neuron or Astrocyte Generation in the Visual Cortex
To determine the functional importance of Chrdl1 to synapse maturation in vivo, we developed a Chrdl1 KO mouse (see STAR Methods). KO of Chrdl1 was confirmed by in situ hybridization and qRT-PCR, with both techniques demonstrating a loss of Chrdl1 mRNA in the KO ( Figures S4A and S4B ). Although we demonstrated that Chrdl1 does not regulate GluA2 AMPARs by inhibiting BMP signaling in vitro (Figure 3 ), we first asked whether other BMP-dependent developmental processes are altered in Chrdl1 KO mice. Inhibition of BMP signaling promotes neurogenesis, and it has been proposed that Chrdl1 promotes a neurogenic fate by inhibiting BMP4 in the adult dentate gyrus (Ueki et al., 2003) . We therefore quantified cortical thickness, neuron number, and astrocyte number in the P14 visual cortex. We found no difference in any of these developmental parameters in the Chrdl1 KO mice compared to littermate wild-type (WT) controls, showing no gross alteration in cell fate has occurred (Figures S5A-S5D). We further performed RNAsequencing analysis of the P14 visual cortex from Chrdl1 KO and WT mice to determine if genes related to BMP signaling, astrocyte development, or synapse formation were altered. No significant differences in gene expression were detected, except for a significant decrease in Chrdl1 in KO mice (Tables S2-S4) , demonstrating that similar to our in vitro results, Chrdl1 does not strongly regulate neuronal gene expression in vivo.
Chrdl1 KO Mice Have Decreased Levels of GluA2 AMPARs at Cortical Synapses
We next asked if features of synapse maturation are altered in the Chrdl1 KO mouse, focusing on synapses formed in the upper layers of the visual cortex at P14, a region where Chrdl1 expression is high and at a time when the switch to GluA2 AMPARs is occurring (Figure 4 ) (Brill and Huguenard, 2008) . To determine if there is an alteration in GluA2 AMPARs present at synapses, we used immunohistochemistry to label GluA2 along with presynaptic markers in P14 visual cortex brain sections and analyzed the upper cortical layers. We first asked if the level of GluA2 at thalamocortical synapses is altered in Chrdl1 KO mice, as these synapses predominantly form in upper cortical layers, by analyzing colocalization of presynaptic vesicular glutamate transporter 2 (VGlut2) with GluA2 ( Figures 5A, 5E , and S6F). This showed a significant $50% decrease in the amount of GluA2 colocalized with VGlut2 in the Chrdl1 KO ( Figure 5B ; 0.54-fold ± 0.03-fold of WT), with smaller but significant decreases in the clustering of each marker alone (Figures 5C and 5D; GluA2, 0.68-fold ± 0.04-fold of WT; VGlut2, 0.77-fold ± 0.03-fold of WT). We then asked if the level of GluA2 at intracortical synapses is also altered by analyzing colocalization of presynaptic vesicular glutamate transporter 1 (VGlut1) with GluA2. We found a significant $20% decrease in the colocalization of VGlut1 with GluA2 in the Chrdl1 KO ( Figure 5F ; 0.80-fold ± 0.09-fold of WT), with a small but significant decrease in GluA2 ( Figure 5G ; 0.90-fold ± 0.05-fold of WT) and no change in VGlut1 ( Figure 5H ; 1.05-fold ± 0.09-fold of WT).
To determine if the decreased colocalization of GluA2 with presynaptic markers specifically reflects a decrease in GluA2 (E and F) Excess BMP ligands block the ability of Chrdl1 to increase surface GluA2 clustering in RGCs. (E) Example images of RGC neurons treated with 1 mg/mL Chrdl1, 250 ng/mL BMP4, 250 ng/mL BMP7, or Chrdl1 and either BMP for 6 days. Top: red labels neurons, and green labels surface GluA2. Bottom: zoom-in view of a dendrite (GluA2, white). Arrowheads mark example GluA2 clusters. (F) Quantification of (E), with surface GluA2 normalized to RGCs alone (no BMP). n = 3 experiments, each with 30 cells per condition. Scale bars, 10 mm. Bar graphs represent mean ± SEM, with individual data points representing experiments. Statistics by one-way ANOVA, with significance as stated on the graph compared to alone. See also Figure S1 and Tables S2 and S3 . at synapses, or if there is also a decrease in synapse number, we used immunohistochemistry to label the postsynaptic density marker PSD95 along with presynaptic markers (Figures 5I and 5M) . At thalamocortical synapses, there was a significant $25% decrease in the amount of PSD95 colocalized with VGlut2 in the Chrdl1 KO ( Figure 5J ; 0.73-fold ± 0.06-fold of WT), with no change in PSD95 and a significant decrease in VGlut2 ( Figures  5K and 5L ; PSD95, 0.93-fold ± 0.06-fold of WT; VGlut2, 0.80fold ± 0.05-fold of WT). At intracortical synapses, we found no difference in colocalization of VGlut1 with PSD95 in the Chrdl1 KO ( Figure 5N ; 0.96-fold ± 0.05-fold of WT) or in PSD95 (Figure 5O ; 1.03-fold ± 0.08-fold of WT) or VGlut1 ( Figure 5P ; 0.98fold ± 0.05-fold of WT). We further asked if absence of Chrdl1 had any effect on synaptic levels of GluA1 (Figures 5Q and 5U) and found that the effect matched that seen with PSD95, namely a 25% decrease in GluA1 colocalized with VGlut2, with no large alteration in GluA1 levels (Figures 5R-5T; colocalized, 0.73fold ± 0.07-fold of WT; GluA1, 0.93-fold ± 0.02-fold of WT; VGlut2, 0.72-fold ± 0.03-fold of WT) and no change in colocalization of GluA1 with VGlut1 ( Figures 5V-5X ; colocalized, 0.99fold ± 0.04-fold of WT; GluA1, 0.98-fold ± 0.03-fold of WT; VGlut1, 1.09-fold ± 0.06-fold of WT). This shows that the strongest effect of Chrdl1 loss is a decrease in GluA2 at excitatory synapses in the developing cortex and that Chrdl1 has a more pronounced role in regulating thalamocortical connections. Interestingly, the expression pattern of Chrdl1 matches the thalamocortical innervation zone, being highest in astrocytes in upper cortical layers, where these synapses form (Figure 4 ).
Chrdl1 KO Mice Have Altered Kinetics of Excitatory Synaptic Events in Cortical Neurons
To ask if the decrease in GluA2 at synapses has any impact on synaptic function, we performed whole-cell patch clamping from layer 2/3 pyramidal neurons in the visual cortex in acute brain slices from P14 Chrdl1 KO and WT littermate controls. We isolated AMPA-mediated mEPSCs by applying AP5 (an NMDA receptor antagonist), bicuculline (a GABAA receptor antagonist), and tetrodotoxin (a sodium channel blocker) (Figure 6A) . We found a significant alteration in the kinetics of mEPSCs, with an increase in the decay time (WT, 3.61 ± 0.14 ms; KO, 4.33 ± 0.19 ms), rise time (WT, 1.04 ± 0.02 ms; KO, 1.17 ± 0.04 ms), and charge transfer (WT, 48.64 ± 1.96; KO, 55.87 ± 2.83) at excitatory synapses onto layer 2/3 cortical neurons in the Chrdl1 KO ( Figures 6B-6E and S6A-S6D), with no change in membrane properties ( Figure S6E ). We did not detect a significant alteration in the frequency (WT, 2.64 ± 0.36 Hz; KO, 2.63 ± 0.25 Hz) or amplitude (WT, 7.58 ± 0.22 pA; KO, 7.39 ± 0.23 pA) of mEPSCs ( Figures 6F and 6G ), suggesting synapses have formed in the absence of Chrdl1, matching the synaptic staining data ( Figures 5I-5P) .
The increase in mEPSC decay time in the absence of Chrdl1 ( Figure 6C ) correlates with our findings in vitro, where adding Chrdl1 protein to neurons had the opposing effect and decreased mEPSC decay time ( Figures 2I and 2L) . In addition to AMPAR composition and location, which we have demonstrated to be altered in Chrdl1 KO mice ( Figure 5 ), a number of other factors can also alter EPSC kinetics (Jonas, 2000) . These include post-translational receptor modifications, interacting proteins, spine morphology, and the removal of glutamate from the synaptic cleft (regulated by glutamate uptake transporters on nearby astrocytes). We therefore asked if there was any alteration in spine morphology (see next section) or the expression and localization of glutamate transporters in astrocytes in Chrdl1 KO mice that could contribute to the observed effect on kinetics.
We found no difference in mRNA level for the glutamate transporters GLT1 (Slc1a2) and GLAST (Slc1a3) between Chrdl1 WT and KO visual cortex at P14 (Table S4) . We then asked if the localization of GLT1 near synapses was altered by performing super-resolution imaging of GLT1 and VGlut2 in Aldh1l1-EGFP mice to label astrocytes at P14 ( Figures 6H and S6G) . We found no significant difference in the amount of GLT1 colocalized with the astrocyte surface between Chrdl1 KO and WT ( Figure 6J ; 0.82-fold ± 0.09-fold of WT). We did detect a significant decrease in VGlut2 puncta ( Figure 6K ; 0.65-fold ± 0.06-fold of WT), repeating the finding we had in the analysis of synapse number ( Figure 5 ). There was a significant decrease in the colocalization of GLT1 present on the astrocyte surface with nearby VGlut2 (Figure 6I ; 0.55-fold ± 0.06-fold of WT), mainly reflective of the decrease in total VGlut2 puncta present in the KO. This suggests glutamate transporters are present at synapses at similar levels between the Chrdl1 KO and WT. We further found no difference in spine morphology between Chrdl1 KO and WT at P28 (see below and Figures 6L-6N) . Overall, these data demonstrate that in the Chrdl1 KO cortex, synapses are present with altered properties and contain less GluA2 AMPARs.
Chrdl1 KO Mice Display Increased Plasticity in the Visual Cortex
In the absence of Chrdl1, synapses in the visual cortex contain less GluA2, suggestive of immature synapses (Figures 5  and 6 ). Based on this, we predicted that Chrdl1 KO mice would show enhanced plasticity and remodeling in the visual cortex in response to altered sensory input. To test this, we used monocular enucleation (ME), either during the critical period, when plasticity is normally present (P28-P32), or in the adult, when there is little plasticity (4 months) (Espinosa and Stryker, 2012) . In this paradigm, one eye is removed, and during the critical period, this leads to characteristic remodeling of synaptic inputs to the binocular zone (BZ) of the visual cortex: a loss of drive from the removed eye and an increase in drive from the intact eye. This can be visualized by stimulating the intact eye with light to activate neurons in the BZ and detecting activated neurons by expression of the immediate early gene Arc ( Figure 7A) (Syken et al., 2006) . The width of the activated zone of neurons is a readout of the level of plasticity, with a wider activation zone meaning more remodeling and plasticity has occurred.
We performed ME at P28 and measured neuronal activation to the intact eye in the BZ 4 days later (at P32), a time period sufficient to allow remodeling. In both the Chrdl1 KO and WT littermate control, there was a significant increase in the width of the BZ activated by the intact eye following ME, showing remodeling has occurred as expected during the critical period ( Figures  7B-7D) . Importantly in the Chrdl1 KO, the increase in the size of the activation zone was significantly larger than in the WT, showing that more remodeling had happened in the absence of Chrdl1. Chrdl1 KO does not affect the developmental targeting of axons to the BZ of the visual cortex, as the width of activation in the normal-rear (NR) condition (visual deprivation for 12 hr) is no different from WT ( Figures 7B-7D ; WT NR, 911 ± 31 mm; KO NR, 902 ± 34 mm; WT ME, 1,321 ± 27 mm; KO ME, 1,484 ± 36 mm).
In mice where neuronally expressed plasticity-limiting molecules are absent (e.g., PirB KO), there is an increase in the density of dendritic spines present at P28 in the absence of plasticity induction, which is thought to act as a substrate for enhanced plasticity potential (Djurisic et al., 2013) . We therefore asked if a similar effect is present in Chrdl1 KO mice by using Golgi staining to visualize dendrites and spines in layer 2/3 neurons at P28 ( Figure 6L) . Quantification of the total protrusions per micrometer of dendrite found no difference between Chrdl1 KO and WT (Figure 6M ; WT, 0.58 ± 0.05 per micrometer; KO, 0.65 ± 0.04 per micrometer). We further asked if there was any alteration in the proportion of spine classes present by classifying spines based on morphology and again found no significant differences between Chrdl1 KO and WT ( Figure 6N ; Risher et al., 2014b) . This similarity in spine density between Chrdl1 KO and WT fits with the similarity in synapse number present between genotypes ( Figure 5) .
We next asked if enhanced plasticity in the absence of Chrdl1 is restricted to development and the critical period or is also present in the adult brain at P120, when Chrdl1 remains expressed ( Figure 4D ; Boisvert et al., 2018) . We performed ME at 4 months of age and analyzed remodeling 4 days and 10 days later, and we included the 10-day time point as this is reported to be sufficient time to allow minimal remodeling in the WT in the adult (Sato and Stryker, 2008) . As in the critical period, we found that more remodeling occurred in the Chrdl1 KO cortex compared to WT in response to ME in the adult. After 4 days, no remodeling had occurred in the WT, whereas there was a significant increase in the width of the activation zone in the Chrdl1 KO, showing the absence of Chrdl1 allowed rapid remodeling to occur (Figures 7E-7G ). After 10 days of deprivation, there was a trend toward an increase in remodeling in the WT adult, which was 2-fold larger and significant in the Chrdl1 KO ( Figures 7E-7G ; WT NR, 1,007 ± 29 mm; KO NR, 1,004 ± 29 mm; WT 4-day ME, 1,066 ± 32 mm; KO 4-day ME, 1,194 ± 28 mm; WT 10-day ME, 1,099 ± 31 mm; KO 10-day ME, 1,196 ± 15 mm). The magnitude of the enhanced plasticity present both during the critical period and in the adult is similar in size to that detected in mice in which neuronal plasticity limiting molecules are removed, such as PirB KO (Djurisic et al., 2013; Syken et al., 2006) . This shows that in the absence of Chrdl1, more remodeling occurs in response to altered sensory input, demonstrating that synapses in the visual cortex have a higher level of plasticity that is maintained into adulthood.
DISCUSSION
In this study, we identified a secreted protein, Chrdl1, which is specifically made by astrocytes in the cortex and is sufficient to increase GluA2 AMPARs at synapses, induce synapse maturation, and inhibit plasticity ( Figure S7) . We further identified that Chrdl1 carries out these functions through an apparently BMPindependent mechanism.
Astrocytes Orchestrate Sequential Development of Synapses
We demonstrate that astrocytes can increase synaptic GluA2 AMPARs and induce synapse maturation via the release of Chrdl1. The increase in calcium-impermeable GluA2 AMPARs is an important step in synapse maturation, and occurs at defined times in the developing cortex (Brill and Huguenard, 2008) . We previously showed that astrocyte-secreted glypican 4 and 6 induce nascent immature synapses to form that contain calcium-permeable GluA1 AMPARs Farhy-Tselnicker et al., 2017) . Both Chrdl1 and glypican 4 are sufficient to induce active synapses to form between neurons in vitro; however, neither factor by itself fully recapitulates the effect of astrocytes on synaptic function. In future it will be important to determine what combinations of these factors, including other synaptogenic molecules such as thrombospondin, are required to fully mimic the astrocyte effect. Expression of glypicans 4 and 6 in astrocytes peaks in the first 2 postnatal weeks, matching the time when immature synapses are forming, whereas expression of Chrdl1 peaks after this time when synapse maturation is occurring (Cahoy et al., 2008) . This suggests that astrocytes can (legend continued on next page) regulate the subtype of AMPAR present at the synapse via the release of different signals. The mechanisms that control the temporal expression of these distinct synaptogenic signals in astrocytes are not known and will be important to identify. For example, are neurons signaling to astrocytes to regulate this switch in synaptogenic potential?
Chrdl1 Has a Heterogeneous Expression Pattern in Astrocytes
Chrdl1 has a heterogeneous expression pattern, being enriched in cortical and striatal astrocytes, and within the cortex Chrdl1 is enriched in astrocytes in upper layers. Our in vivo data showed a significant decrease in GluA2 at excitatory synapses in upper cortical layers in Chrdl1 KO mice, with a stronger reduction at thalamocortical synapses compared to intracortical synapses. Thalamocortical synapses predominantly form in upper layers of the cortex, where Chrdl1 expression is highest (Cruz-Martín et Seabrook et al., 2017) , and undergo plasticity following visual deprivation (Espinosa and Stryker, 2012) , which is enhanced in Chrdl1 KO mice. Other astrocyte-secreted synaptogenic molecules, such as Sparcl1 and thrombospondin, have differential effects on intracortical compared to thalamocortical synapses, but these molecules have a homogeneous expression pattern throughout the cortical layers in contrast to the restricted expression of Chrdl1 (Eroglu et al., 2009; Risher et al., 2014a) . The factors that determine the heterogeneous expression of Chrdl1, and correlation with thalamocortical innervation zones, will be important to determine. Further, the restricted spatial expression pattern of astrocyte Chrdl1 in the cortex and striatum suggests that in other brain regions, additional as-yet-unidentified astrocyte-secreted factors may be regulating synapse maturation. Alternatively, Chrdl1 may be enriched in brain regions where the circuit needs to remain stable for correct function once developmental remodeling has occurred. For example, the end of the critical period in the visual cortex marks the time when binocular matching is complete, and it would be detrimental if changes in visual input altered this connectivity. Of note, Chrdl1 is absent from the hippocampus, a region of the brain where synapses continue to remodel throughout life, so we hypothesize that its absence allows this remodeling to occur.
Chrdl1 Regulates Synapse Maturation Independently of BMP Signaling
Identifying the mechanism of how Chrdl1 regulates synaptic levels of GluA2 and synapse maturation will give important insight into the mechanism of plasticity regulation. Chrdl1 was identified as a secreted antagonist of BMP signaling; however, we found that Chrdl1-induced recruitment of GluA2 AMPARs to synapses appears to occur in a BMP-independent manner and that other secreted BMP antagonists, such as noggin and chordin, do not mimic its effect. Although BMP signaling is not required, the CR repeats or vWFC domains, which bind BMPs, are required for Chrdl1-induced GluA2 recruitment. vWFC domains are present in a number of extracellular proteins, including chordins, integrins, collagens, and thrombospondins, and allow complex formation and interaction with multiple proteins (Hunt and Barker, 1987 ). An example is integrins, which bind a number of vWFC-containing proteins, including collagens and thrombospondins (Humphries et al., 2006) , and integrins themselves can regulate GluA2 synaptic recruitment (Park and Goda, 2016) . The secreted BMP inhibitor Brorin, which also contains CR repeats, has been identified in proteomic studies as an interactor of GluA2 AMPAR complexes, but not GluA1 AMPAR complexes (Koike et al., 2007; Schwenk et al., 2012) . As Chrdl1 specifically regulates GluA2 AMPARs, an intriguing possibility is that it is doing so by physically interacting with GluA2 complexes.
Chrdl1 Represses Plasticity
Previous work has demonstrated a role for glial-secreted molecules such as Sparcl1 and tumor necrosis factor a (TNF-a) in enabling plasticity to occur in the visual cortex in response to visual deprivation (Kaneko et al., 2008; Singh et al., 2016) . We now show that astrocytes can induce the opposite effect via release of Chrdl1 to repress plasticity. This suggests that astrocytes, through the release of distinct signals, have the ability to regulate the neuronal environment to either allow or repress synaptic plasticity. In the future, it will be important to determine how removal of Chrdl1 allows enhanced plasticity to occur. For example, neuronal molecules that repress plasticity (e.g., PirB), when knocked out, show altered longterm potentiation (LTP), long-term depression (LTD), and increased spine density in the visual cortex (Djurisic et al., 2013) . We found no effect on spine density in Chrdl1 KO mice, however, arguing against a deficit in synapse elimination being responsible for the enhanced plasticity. Identifying the molecular mechanism of how Chrdl1 increases synaptic GluA2 will give important insight into the mechanism of altered plasticity.
In humans, null mutations in Chrdl1 cause X-linked megalocornea 1 (MGC1), which is associated with enlarged corneas and an increased risk of cataracts with age (Webb et al., 2012) . Interestingly, cognitive testing of MGC1 patients revealed a superior verbal IQ, verbal memory, and executive skills (Webb et al., 2012) . As Chrdl1 KO mice show enhanced plasticity in the visual cortex, it would be interesting to determine if a similar mechanism is contributing to the enhanced cognitive performance seen in MGC1. Further, transcriptomic profiling of cortical samples from patients with schizophrenia and bipolar disorder identified significantly upregulated Chrdl1 mRNA in both disorders, suggesting the absolute level of Chrdl1 is important for regulating synaptic function (Gandal et al., 2018) . The actions of Chrdl1 in inhibiting plasticity are not restricted to development but continue throughout life into the adult. This is particularly important when considering situations where it would be beneficial to reopen plasticity in the adult brain (e.g., to encourage Tables S2-S4. synaptic repair after injury such as a stroke). Manipulating Chrdl1 could provide a new avenue of investigation for post-injury treatments, especially at older ages, when plasticity declines (Burke and Barnes, 2006; Henley and Wilkinson, 2013) . Taken together, this study demonstrates that astrocytes, via the release of Chrdl1, are essential for synapse maturation and play important roles in regulating plasticity in the brain.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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(E) Example images from WT and Chrdl1 KO BZ at 4 months, from normal rear (NR; 12-hr visual deprivation) and ME (4-day or 10-day visual deprivation) showing active neurons marked by mRNA for Arc (white). Asterisks (*) mark boundaries of activated neurons. Representative image is cropped from a mosaic of 143 stitched tiles.
(F) Analysis of the width of zone of activated neurons in layer 4 of the BZ shows enhanced plasticity occurs in response to 4 days and 10 days of ME in the Chrdl1 KO in the adult. (G) Cumulative distribution plots of width of BZ activation in the adult, where each point represents an individual brain section. Statistical comparison of distribution by Kolmogorov-Smirnov test: WT versus KO NR, p = 0.98; WT versus KO 4 day ME, p = 0.008; WT versus KO 10 day ME, p = 0.001; WT NR versus 4 day ME, p = 0.1; WT NR versus 10 day ME, p = 0.04; KO NR versus 4 day ME, p = 0.0001; KO NR versus 10 day ME, p = <0.0001. n = 5 WT, 5 KO mice for NR, ME 4 day and ME 10 day. Scale bars, 200 mm. Bar graphs represent mean ± SEM, with individual data points representing mice. Statistics by two-way ANOVA, with significance as stated on the graph. 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Nicola J. Allen (nallen@salk.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals
All animal work was approved by the Institutional Animal Care and Use Committee (IACUC) of the Salk Institute for Biological Studies.
Rats
Sprague Dawley rats (Charles River stock number 001) were housed in the Salk Institute animal facility at a light cycle of 12 hr light: 12 hr dark, with access to water and food ad libitum. Rat pups of both genders were used for preparing astrocyte and neuron cell culture experiments, as described below.
Mice
Mice were housed in the Salk Institute animal facility at a light cycle of 12 hr light: 12 hr dark, with access to water and food ad libitum. Wild-type (WT) mice WT C57BL/6J (Jax stock number 000664) mice were used for analysis of developmental expression of Chrdl1 (qRT-PCR and in situ hybridization, see below), and to breed to Chrdl1 KO mice. Mice of both genders were used. Chrdl1 germline knockout (KO) mice Chrdl1 KO mice were generated using CRIPSR-cas9 technology to introduce a 2 nucleotide deletion in exon 3 of the gene, introducing a premature stop codon (see below for detailed procedure). Mice carrying the mutation were backcrossed to C57BL/6J (Jax stock number 000664) for at least three generations before experiments. Chrdl1 is on the X chromosome, so for the generation of experimental mice heterozygous (+/À) Chrdl1 females were bred to WT (+/y) C57BL/6J males. All experiments were performed using male Chrdl1 KO (-/y) and WT (+/y) littermates.
Astrocyte-specific Ribotag mice
To obtain HA-tagging of ribosomes in astrocytes to enable purification of astrocyte-enriched mRNA, 
Retinal ganglion cell neuron cultures
Retinal ganglion cell neurons (RGC) were isolated from P5-7 Sprague Dawley rat retinas (Charles River) as previously described (Ullian et al., 2001) . RGCs were plated on glass coverslips (12mm diameter, Carolina Biological Supply 633029) coated with poly-D-lysine (Sigma P6407) and laminin (R&D 340001001) at a density of 30,000 cells/well. RGC growth media contained: 50% DMEM (Thermo Fisher Scientific 11960044), 50% Neurobasal (Thermo Fisher Scientific 21103049), Penicillin-Streptomycin (LifeTech 15140-122), glutamax (Thermo Fisher Scientific 35050-061), sodium pyruvate (Thermo Fisher Scientific 11360-070), N-acetyl-Lcysteine (Sigma A8199), insulin (Sigma I1882), triiodo-thyronine (Sigma T6397), SATO (containing: transferrin (Sigma T-1147), BSA (Sigma A-4161), progesterone (Sigma P6149), putrescine (Sigma P5780), sodium selenite (Sigma S9133)), B27 (see (Winzeler and Wang, 2013) for recipe), BDNF (Peprotech 450-02), CNTF (Peprotech 450-13), and forskolin (Sigma F6886). RGC cultures were maintained in a humidified incubator at 37 C and 10% CO 2 . Cortical astrocyte cultures Astrocytes were obtained from the cerebral cortex of P1-2 Sprague Dawley rats (Charles River) as previously described McCarthy and de Vellis, 1980) . Astrocytes were plated on 75 cm 2 tissue culture flasks coated with poly-D-lysine (Sigma P6407) and maintained in culture for 4 days in growth medium (DMEM (Thermo Fisher Scientific 11960044) supplemented with 10% heat inactivated FBS (Thermo Fisher Scientific 10437028), Penicillin-Streptomycin (Thermo Fisher Scientific 15140-122), glutamax (Thermo Fisher Scientific 35050-061), sodium pyruvate (Thermo Fisher Scientific 11360-070), hydrocortisone (Sigma H0888), and N-acetyl-L-cysteine (Sigma A8199)). Flasks were then shaken vigorously to remove cells on overgrown layers. Two days later AraC (working concentration 10 mM; Sigma C1768) was added for 48 hr in order to inhibit rapidly proliferating cells. Astrocytes were then plated on 15 cm tissue culture dishes and maintained in growth media. They were passaged once a week and cultures were maintained for no longer than 4 weeks. Depending on the experimental purpose, astrocytes were plated on inserts (Thermo Fisher Scientific 353104) 4 days before they were applied to RGC cultures at a density of 50,000 cells per insert or plated on 10cm cell culture dishes at a density of 500,000 cells per dish to collect secreted proteins as conditioned media. Astrocyte cultures were maintained in a humidified incubator at 37 C and 10% CO 2 .
METHOD DETAILS
Collection of astrocyte or neuron secreted proteins Astrocytes grown in 10 cm tissue culture dishes were washed 3 times with warm DPBS (HyClone SH30264) to remove the serumcontaining growth media, and the growth media was replaced by minimal low protein conditioning media (50% DMEM, 50% Neurobasal, penicillin-streptomycin, glutamax and sodium pyruvate). Astrocytes were conditioned in low protein media for 4 days in a tissue culture incubator at 37 C 10% CO 2 . The astrocyte conditioned media (ACM) was collected and concentrated 100-fold using Vivaspin 20 centrifugal concentrators with a MW cut-off of 10kDa (Sartorius 14558502). Protein concentration of the ACM was assessed by Bradford protein assay (Bio-Rad 500-0006).
For western blots in Figure S1B , astrocytes or RGC neurons were grown in 6-well plates in appropriate growth media as detailed above. Cultures were washed 3 times with warm DPBS and the growth media was replaced by minimal low protein conditioning media (50% DMEM, 50% Neurobasal, penicillin-streptomycin, glutamax, sodium pyruvate, N-acetyl cysteine, forskolin, BDNF, CNTF) for 4 days, and collected as outlined above. Western blotting of conditioned media was used to compare secretion of Chrdl1 from neurons to secretion of Chrdl1 from astrocytes.
Column fractionation and mass spectrometry analysis
Astrocyte conditioned media (ACM) was collected from rat astrocyte cultures and concentrated (see above). Concentrated ACM underwent column fractionation as previously described, using an anion exchange column (HiTrap Q HP, GE Healthcare 17-1153-01) . GluA2 live staining (see below) was performed on RGC cultures after treatment with the different fractions for 6 days, to assess which fraction contained the factor that recruited GluA2 AMPAR subunits to the neuronal surface. The positive fraction (unbound proteins from an anion exchange column) was analyzed by the Stanford University Mass gel (NW00120BOX) were used for SDS-PAGE and proteins were transferred as described previously. Rabbit anti-Chrdl1 (Sigma HPA000250) at a dilution 1:250 was used for immunoblotting in order to prevent detection of the heavy and light chain of the mouse anti-Chrdl1 used in the immunoprecipitation.
absolute ethanol 4 times for 4 min each, and cleared in xylene 3 times for 4 min. Slides were mounted using Permount (Fisher Scientific SP15-100). Pyramidal neurons from layers 2/3 within the visual cortex were imaged in brightfield in a Zeiss Axio Imager.Z2 microscope, using the 63X oil-immersion objective as a z stack of 160 slices with a total thickness of 80 mm. Z stacks were transformed in ImageJ (NIH) to RGB images, and saved as image sequences. Spines located in sections of secondary and tertiary dendrites of pyramidal cortical neurons within the upper layers of the visual cortex were analyzed. Length and width of spines were assessed using Reconstruct software (Fiala, 2005) . Analysis and classification of spine morphology was assessed according to (Risher et al., 2014b) . A total of 5 littermate Chrdl1 KO and WT mice were analyzed, with 9 neurons per mouse, and 3 dendrites per neuron analyzed.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical tests and graphs were designed using Prism 7 and Sigmaplot, all tests are two-tailed. Student's t test was used to compare two groups. To compare more than two groups, one-way ANOVA with Dunnett's post hoc test for multiple comparisons was used. When data did not pass normal distribution test, multiple comparisons were done by Kruskal-Wallis ANOVA on ranks and pairwise comparisons were done with Mann-Whitney Rank Sum test. For analysis of monocular enucleation a two-way ANOVA was used. To compare distributions a Kolmogorov-Smirnov (K-S) test was run in MiniAnalysis (Synaptosoft). Exact p values reported on graphs.
DATA AND SOFTWARE AVAILABILITY
RNA sequencing data have been deposited at GEO: GSE108483 (Chrdl1 KO and WT mouse visual cortex). GSE108484 (Rat RGC neurons ± Chrdl1 protein treatment).
The data that support the findings of this study are available from the lead contact upon reasonable request.
